一分钟看懂
这是一项关于肝细胞癌的II 期研究，登记的药物或干预包括Iparomlimab and Tuvonralimab (QL1706)；Lenvatinib；Radiotherapy；hepatic arterial infusion chemotherapy (HAIC)，当前状态为招募中。登记地点显示中国武汉有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Iparomlimab and Tuvonralimab (QL1706)；Lenvatinib；Radiotherapy；hepatic arterial infusion chemotherapy (HAIC) · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China · 武汉
公开的入选条件
- 1. Age ≥18 and ≤75 years at the time of signing informed consent.
- 2. Histologically or clinically confirmed hepatocellular carcinoma (HCC) according to the 2024 Chinese Guidelines for the Diagnosis and Treatment of Primary Liver Cancer.
- 3. Radiologically confirmed portal vein tumor thrombus (PVTT), classified as Cheng type I-IV.
- 4. No prior systemic or local treatment directed at PVTT, including targeted therapy, immunotherapy, or systemic chemotherapy.
- 5. Child-Pugh class A or B with a Child-Pugh score ≤7.
- 6. Considered unsuitable for curative surgery or liver transplantation after multidisciplinary evaluation, but suitable for radiotherapy.
- 7. Adequate organ function, including: WBC ≥3.0 × 10⁹/L; PLT ≥50 × 10⁹/L; hemoglobin ≥80 g/L; ALT ≤5 × ULN; AST ≤5 × ULN; total bilirubin ≤3 × ULN; albumin ≥28 g/L; and creatinine clearance ≥80 mL/min.
- 8. At least one measurable lesion according to mRECIST.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07776080；登记信息更新于 2026-09-15。